Gene Logic Integrates Both Xenogen's Proprietary Biophotonic Imaging
Technology and Custom Animal Model Generation into Its New Drug Repositioning
and Selection Business
ALAMEDA, Calif., Oct. 13 /PRNewswire-FirstCall/ -- Xenogen Corporation
(Nasdaq: XGEN) announced today an agreement with Gene Logic Inc.
(Nasdaq: GLGC). Xenogen Biosciences Corporation, Xenogen's wholly owned
subsidiary, is producing and characterizing lines of custom-produced
bioluminescent animal models for Gene Logic. This deal follows a November
2004 agreement in which Gene Logic purchased Xenogen equipment and licensed
Xenogen's proprietary biophotonic imaging technology. Gene Logic has
integrated Xenogen's technology into its new Drug Repositioning and
Selection(TM) (DRS) collaborations.
Under the November 2004 agreement, Gene Logic purchased Xenogen's
biophotonic imaging systems, IVIS(R) Imaging System 200 Series, and licensed
the company's proprietary Living Image(R) Software and patented methods of
biophotonic imaging. Under the April 2005 agreement, Gene Logic received a
license grant to the customized bioluminescent animal models it is producing
together with Xenogen Biosciences for use in Gene Logic's new DRS
collaborations. Gene Logic has combined its own proprietary imaging methods
with Xenogen's technology to form an important part of its overall drug-
repositioning platform.
"Xenogen's biophotonic imaging technology is one of a number of key
technologies that we are in-licensing and/or developing for our new
repositioning and selection program," said Louis Tartaglia, Ph.D., senior vice
president and general manager, Drug Repositioning and Selection for Gene
Logic. "This technology, in combination with proprietary methods developed at
Gene Logic, provides us with an important new way of non-invasively imaging
whole animals over time and essentially lighting up the biological processes
or responses to the compound we're testing. We believe this will help us
generate valuable predictive data on how a drug affects the whole system.
These data are not available with conventional research methods."
Gene Logic's DRS collaborations are based, in part, on technologies the
company acquired in 2004 from Millennium Pharmaceuticals, Inc. These
technologies include in vivo real-time imaging; disease metabolomics; disease-
relevant in vitro pathway and cellular screening; and predictive and genetic
ADME. When combined with Gene Logic's existing genomics and toxicogenomics
capabilities and in silico analysis, DRS collaborations are designed to enable
Gene Logic to help pharmaceutical partners identify alternative indications
for failed, stalled or de-prioritized drug candidates, expand indications for
currently marketed drugs, and prioritize and identify indications for drug
candidates entering pre-clinical development.
"Gene Logic has developed an exciting new business and scientific
opportunity to reposition drug compounds for new indications, and we are
pleased that our technology can play a role in that effort," said Pamela
Contag, Ph.D., president of Xenogen Corporation. "Gene Logic recognized the
benefits of Xenogen's non-invasive molecular and functional imaging technology
for prioritizing targets and compound indications early in the drug discovery
and development process or later in the process to find new development paths
for clinical-stage drug candidates."
About Xenogen Corporation
Xenogen Corporation is a leading biotechnology company offering an
integrated suite of biophotonic real-time in vivo imaging and genetic
modification technologies that can help expedite drug discovery and
development, and significantly reduce the cost and time to market for new
therapies. Xenogen's VivoVision(TM) Systems non-invasively illuminate and
monitor biological processes within living mammals, at the molecular level, in
real time. The technology provides higher quality in vivo data earlier in the
drug discovery and development process. VivoVision(TM) Solutions improve
discovery and pre-clinical research in multiple therapeutic areas.
VivoVision(TM) Biosciences represents more than 15 years of experience in the
creation and characterization of animal models, including genetic
modifications, comprehensive phenotyping, compound profiling and custom design
and production of light producing cells, microorganisms and animals.
More information is available at http://www.xenogen.com. Xenogen(R), Living
Image(R), VivoVision(TM) and IVIS(R) are trademarks of Xenogen Corporation.
Forward-Looking Statements
This press release contains forward-looking statements regarding the
performance and intended uses of our imaging products and technologies. These
forward-looking statements are based on our current expectations, estimates
and assumptions and are subject to many risks, uncertainties and unknown
future events that could cause actual results to differ materially. Actual use
and results of imaging products and technologies may differ materially from
those set forth in this release due to the risks and uncertainties inherent in
our business, including, without limitation: our ability to continue to
deliver our products on a timely basis; our ability to enforce our
intellectual property rights or operate without infringing or misappropriating
the proprietary rights of others; products, services or technologies
introduced by competing companies; and other risk factors set forth in our
filings with the Securities and Exchange Commission. For a discussion of
these and other factors that could impact the performance or use of our
imaging products and technologies and cause them to differ materially from
those in the forward-looking statements, please refer to our recent filings
with the Securities and Exchange Commission, including our most recent
quarterly report on Form 10-Q for the quarter ended June 30, 2005. We assume
no obligation to update any forward-looking statements or information, which
speak as of their respective dates.
Available Topic Expert(s): For information on the listed expert(s), click
appropriate link.
Pamela R. Contag, Ph.D.
http://profnet.prnewswire.com/ud_public.jsp?userid=513625
David W. Carter
http://profnet.prnewswire.com/ud_public.jsp?userid=513851
SOURCE Xenogen Corporation
 back to top
Related links:
http://www.xenogen.com
CONTACT:
investors, William A. Albright of Xenogen
Corporation, +1-510-291-6100, or media, Kelly McKenna of Manning
Selvage & Lee, +1-415-278-3318, for Xenogen Corporation
|
